ReviewAdvanced healthcare materials2026
Blood-Brain Barrier Regulation: Evolving From Classic Strategies to Electrochemical Ion and Reactive Oxygen Species Control.
Review in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The blood-brain barrier (BBB), while indispensable for maintaining central nervous system (CNS) homeostasis, constitutes the principal impediment to effective therapeutic delivery for neurodegenerative disorders, particularly hindering spatially resolved modulation of extracellular ions and reactive oxygen species (ROS) within the neural microenvironment. Contemporary electrochemical methodologies have emerged as a paradigm shift for dynamically reconciling these dual parameters, thereby enabling targeted neuroregulation. Critical review of this field reveals a distinct evolution from passive physiological interventions to active electrochemical engineering approaches. Current research, however, encounters persistent translational barriers including insufficient spatiotemporal resolution in neural interfaces, incomplete mechanistic understanding of ROS-ionic crosstalk, and scalability limitations of nanoscale delivery systems. To transcend these limitations, the synergistic convergence of electrochemical platforms with machine learning (ML)-guided predictive analytics, near-infrared (NIR) phototherapy, and biocompatible nanocarrier-mediated delivery systems constitutes a strategic imperative in next-generation neurotherapeutic development. Such interdisciplinary convergence is not merely incremental but rather a fundamental prerequisite for realizing clinically translatable neural microenvironment modulation.
Indexed as
Identifiers
42701919What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.